
Pierre Fabre amends license agreement with Puma Biotechnology
According the extended agreement, Pierre Fabre may not only market the breast cancer recurrence blocker Nerlynx® (neratinib) within Europe and...

Healx Ltd raises $56m in Series B financing
The financing was led by Atomico and joined by Intel Capital, Global Brain and btov Partners as new investors. Existing investors from a US$10m...

ADC Therapeutics enters licence option deal with Avacta Group
Under the terms of the agreement, Avacta Group (Cambridge, UK) will provide three small Affimer proteins designed to bind to undisclosed cancer...

Rotavirus vaccines kill cancer cells
The team headed by Aurelian Marabelle discovered in mice that commercially available vaccines against rotavirus – which causes diarrhea in children...

Researchers identify CTLA-4 response marker
The research team headed by Simon Heideger and Hendrick Poeck from Technical University of Munich together with colleagues from Memorial Sloan...

AMR: GARDP and Entasis Therapeutics start pivotal study
In the open-label study enroling 1,000 patients, safety and efficacy of zoliflodacin will be compared with a combination of azithromycin and...

Cellectis presents way to safer CAR-Ts
The company presented the in vitro "proof-of-concept" of their new CAR-T cells, in which they integrated a gene network that senses tumour...